Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1

被引:27
作者
Fan, Haihong
Li, Huaina
Zhang, Mingyu
Middaugh, C. Russell
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[2] Phage Biotechnol Corp, Irvine, CA 92617 USA
关键词
circular dichroism; UV/Vis spectroscopy; physical characterization; fluorescence spectroscopy; excipients;
D O I
10.1002/jps.20796
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A variety of solutes are commonly used to increase the stability of protein in therapeutic formulations. An empirical phase diagram approach is used to evaluate the effects of different types of additives on the solution behavior of a protein of pharmaceutical interest, human fibroblast growth factor 1 (FGF-1). A specific stabilizer, heparin, and a nonspecific stabilizer, sucrose, were used in this work. The protein was characterized as a function of pH (3-8) and temperature (10-85 degrees C) using Far-IN circular dichroism (Far-IN CD), intrinsic and extrinsic fluorescence as well as second derivative UV absorption spectroscopy. Empirical phase diagrams were constructed to summarize the biophysical characterization data obtained with FGF-l alone, in the presence of a threefold weight excess of heparin (3 x heparin) or 10% sucrose (w/v). Three phases are observed in the low temperature regions at pH 3,4, and 5-8. Phase boundaries corresponding to major heat-induced transitions are detected in the physiological temperature range. The highest thermal stabilities are observed near neutral pH (pH 6 and 7). Both heparin and sucrose appear to enhance the thermal stability of FGF-1, although their effects on the phase diagram are quite distinct. The greatest stabilization is observed at pH 8. Only heparin appears to protect FGF-1 from acid-induced unfolding to any extent. (C) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1490 / 1503
页数:14
相关论文
共 46 条
[11]   HEPARIN PROTECTS BASIC AND ACIDIC FGF FROM INACTIVATION [J].
GOSPODAROWICZ, D ;
CHENG, J .
JOURNAL OF CELLULAR PHYSIOLOGY, 1986, 128 (03) :475-484
[12]   IDENTIFICATION OF THE DOMAIN WITHIN FIBROBLAST GROWTH-FACTOR-I RESPONSIBLE FOR HEPARIN-DEPENDENCE [J].
IMAMURA, T ;
FRIEDMAN, SA ;
GAMBLE, S ;
TOKITA, Y ;
OPALENIK, SR ;
THOMPSON, JA ;
MACIAG, T .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1995, 1266 (02) :124-130
[13]   Anthrax vaccine powder formulations for nasal mucosal delivery [J].
Jiang, G ;
Joshi, SB ;
Peek, LJ ;
Brandau, DT ;
Huang, J ;
Ferriter, MS ;
Woodley, WD ;
Ford, BM ;
Mar, KD ;
Mikszta, JA ;
Hwang, CR ;
Ulrich, R ;
Harvey, NG ;
Middaugh, CR ;
Sullivan, VJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) :80-96
[14]  
Kendrick Brent S, 2002, Pharm Biotechnol, V13, P61
[15]   Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state [J].
Kendrick, BS ;
Chang, BS ;
Arakawa, T ;
Peterson, B ;
Randolph, TW ;
Manning, MC ;
Carpenter, JF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) :11917-11922
[16]  
Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4
[17]   Kinetic and thermodynamic stabilization of the βγ-crystallin homolog spherulin 3a from Physarum polycephalum by calcium binding [J].
Kretschmar, W ;
Mayr, EM ;
Jaenicke, R .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 289 (04) :701-705
[18]   Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study [J].
Kueltzo, LA ;
Ersoy, B ;
Ralston, JP ;
Middaugh, CR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (09) :1805-1820
[19]  
LEE JC, 1981, J BIOL CHEM, V256, P7193
[20]   Disulfide Bonds are Neither Required, Present, Nor Compatible with Full Activity of Human Recombinant Acidic Fibroblast Growth Factor [J].
Linemeyer, David L. ;
Menke, John G. ;
Kelly, Linda J. ;
Disalvo, Jerry ;
Soderman, Denis ;
Schaeffer, M. -T. ;
Ortega, Sagrario ;
Gimenez-Gallego, Guillermo ;
Thomas, Kenneth A. .
GROWTH FACTORS, 1990, 3 (04) :287-298